We are live on ! Find out more
ACP

Acuta Capital Partners Portfolio holdings

AUM $142M
1-Year Est. Return 783.79%
This Fund
S&P 500
This Quarter Est. Return
-4.76%
1 Year Est. Return
+783.79%
3 Year Est. Return
+7,472.18%
5 Year Est. Return
+13,792.16%
10 Year Est. Return
+1,629,663.73%
AUM
$86.2M
AUM Growth
-$13.2M
Cap. Flow
-$1.05M
Cap. Flow %
-1.22%
Top 10 Hldgs %
64.54%
Holding
46
New
7
Increased
19
Reduced
6
Closed
12

Top Buys

Rank Stock Value
1
WHWK
Whitehawk Therapeutics
WHWK
+$4.08M
2
SLNO
Soleno Therapeutics
SLNO
+$3.27M
3
OCS icon
Oculis Holding
OCS
+$2.56M
4
MRK icon
Merck
MRK
+$2.15M
5
SRZN icon
Surrozen
SRZN
+$1.98M

Top Sells

Rank Stock Value
1
CRNX icon
Crinetics Pharmaceuticals
CRNX
+$6.28M
2
PCVX icon
Vaxcyte
PCVX
+$3.68M
3
RVMD icon
Revolution Medicines
RVMD
+$1.83M
4
MRSN
Mersana Therapeutics
MRSN
+$1.6M
5
TSHA icon
Taysha Gene Therapies
TSHA
+$1.53M

Sector Composition

Rank Sector Weight
1 Healthcare 99.98%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ZYME icon
26
Zymeworks
ZYME
$1.75B
$815K 0.95%
68,459
+1,219
+2% +$16.6K
RARE icon
27
Ultragenyx Pharmaceutical
RARE
$2.55B
$771K 0.89%
21,290
+290
+1% +$12.1K
VERV
28
DELISTED
Verve Therapeutics
VERV
$744K 0.86%
162,724
+2,524
+2% +$16.9K
RCKT icon
29
Rocket Pharmaceuticals
RCKT
$391M
$556K 0.64%
83,350
-51,150
-38% -$505K
RAPP
30
Rapport Therapeutics
RAPP
$2.17B
$164K 0.19%
16,400
– –
FBRX icon
31
Forte Biosciences
FBRX
$1.57B
$143K 0.17%
18,469
+330
+2% +$3.9K
ARTV
32
Artiva Biotherapeutics
ARTV
$556M
$136K 0.16%
45,456
+1,456
+3% +$7.86K
NUVB.WS
33
DELISTED
Nuvation Bio Inc Warrants
NUVB.WS
$17.5K 0.02%
90,832
– –
ACLX
34
DELISTED
Arcellx
ACLX
– –
-10,743
Closed -$824K
CELC icon
35
Celcuity
CELC
$4.48B
– –
-25,000
Closed -$327K
CRNX icon
36
Crinetics Pharmaceuticals
CRNX
$8.9B
– –
-122,900
Closed -$6.28M
CRVS icon
37
Corvus Pharmaceuticals
CRVS
$1.15B
– –
-74,307
Closed -$398K
ELDN icon
38
Eledon Pharmaceuticals
ELDN
$272M
– –
-235,750
Closed -$971K
MRSN
39
DELISTED
Mersana Therapeutics
MRSN
– –
-44,820
Closed -$1.6M
NAMS icon
40
NewAmsterdam Pharma
NAMS
$3.32B
– –
-50,000
Closed -$1.28M
PCVX icon
41
Vaxcyte
PCVX
$8.62B
– –
-45,000
Closed -$3.68M
SGMO
42
DELISTED
SANGAMO THERAPEUTICS INC
SGMO
– –
-740,000
Closed -$755K
THRD
43
DELISTED
Third Harmonic Bio
THRD
– –
-49,800
Closed -$512K
TSHA icon
44
Taysha Gene Therapies
TSHA
$1.86B
– –
-884,244
Closed -$1.53M
TECX
45
Tectonic Therapeutic
TECX
$582M
– –
-33,008
Closed -$1.52M
1
2

Similar funds

EC
EJF Capital Arlington, Virginia $142M AUM 23.3% 1-Year Est. Return
YEPX
Yorktown Energy Partners XI New York $142M AUM 130.51% 1-Year Est. Return
SR
Summer Road West Palm Beach, Florida $142M AUM 43.61% 1-Year Est. Return
IA
IF Advisors San Antonio, Texas $141M AUM
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return
POIA
Pin Oak Investment Advisors Houston, Texas $141M AUM 20.83% 1-Year Est. Return
TM
TFJ Management Somerville, Massachusetts $141M AUM 9.28% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM

Acuta Capital Partners's Q1 2025 Portfolio in Review

As of Q1 2025, Acuta Capital Partners held 46 positions worth $86.2M, down 13% from $99.4M the previous quarter. Its ten largest holdings account for 65% of the portfolio.

Acuta Capital Partners's Q1 2025 filing shows 7 new, 19 increased, 6 reduced and 12 closed positions. Its largest new stake was Soleno Therapeutics: 67,136 shares worth $4.8M. The largest sale was Crinetics Pharmaceuticals, an estimated $6.28M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

  • Acuta Capital Partners's largest Q1 2025 buy was Soleno Therapeutics: 67,136 shares worth $4.8M.
  • Acuta Capital Partners added most to Whitehawk Therapeutics in Q1 2025, an estimated $4.08M increase.
  • Acuta Capital Partners's biggest Q1 2025 reduction was Revolution Medicines, cutting an estimated $1.83M.
  • Acuta Capital Partners fully exited Crinetics Pharmaceuticals in Q1 2025, selling an estimated $6.28M.
  • Acuta Capital Partners's ten largest holdings make up 65% of its $86.2M portfolio in Q1 2025.
  • Acuta Capital Partners opened 7 new positions and closed 12 in Q1 2025.
  • Acuta Capital Partners's portfolio value fell 13% quarter-over-quarter to $86.2M.

Based on Acuta Capital Partners's 13F filing for Q1 2025, filed 15 May 2025.